tiprankstipranks
Humacyte announces FDA approval for Symvess
The Fly

Humacyte announces FDA approval for Symvess

Humacyte (HUMA) announced that the FDA has granted a full approval for Symvess for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and when autologous vein graft is not feasible.

Don't Miss Our New Year's Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App